Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.32 |
| ▸ | KDM4A | O75164 | 1/20 | 0.32 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL236829 | 1.00 | LMNA (0.50) | LMNAKDM4CKDM4APHF8KDM2A | |
| SCHEMBL1879316 | 1.00 | LMNA (0.50) | LMNAKDM4CKDM4APHF8KDM2A | |
| SCHEMBL676890 | 1.00 | LMNA (0.50) | LMNAKDM4CKDM4APHF8KDM2A | |
| SCHEMBL1881654 | 1.00 | LMNA (0.50) | LMNAKDM4CKDM4APHF8KDM2A | |
| SCHEMBL42829 | 1.00 | LMNA (0.50) | LMNAKDM4CKDM4APHF8KDM2A | |
| SCHEMBL1042212 | 1.00 | LMNA (0.50) | LMNAKDM4CKDM4APHF8KDM2A | |
| SCHEMBL235652 | 1.00 | LMNA (0.50) | LMNAKDM4CKDM4APHF8KDM2A | |
| SCHEMBL43912 | 1.00 | LMNA (0.50) | LMNAKDM4CKDM4APHF8KDM2A | |
| SCHEMBL1886292 | 1.00 | LMNA (0.50) | LMNAKDM4CKDM4APHF8KDM2A | |
| SCHEMBL57302 | 1.00 | LMNA (0.50) | LMNAKDM4CKDM4APHF8KDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018050484-A1 | LUBRICANT COMPOSITIONS CONTAINING DIUREA COMPOUNDS | BASF SE (DE) | 2018-03-22 | — | — | WO | claimed |
| EP-3293246-A1 | LUBRICANT COMPOSITIONS CONTAINING DIUREA COMPOUNDS | BASF SE (DE) | 2018-03-14 | — | — | EP | claimed |
| WO-2007149842-A2 | METHOD OF PREPARING IMIDAZOLIUM SURFACTANTS | BRIDGESTONE CORPORATION (JP) | 2007-12-27 | — | — | WO | claimed |
| US-20070293684-A1 | Method of preparing imidazolium surfactants | BRIDGESTONE CORPORATION | 2007-12-20 | — | — | US | claimed |
| US-20070161734-A1 | Comprising clay and cationic mediator such as imidazolium compound wherein cationic mediator comprises hydrophobic unit and cationic unit; use in preparing products such as tires with improved and well-balanced properties including gas impermeability, cure rates, and superior mechanical characteristics | BRIDGESTONE CORPORATION (JP) | 2007-07-12 | — | — | US | claimed |
| US-20060173115-A1 | Nano-composite and compositions manufactured thereof | BRIDGESTONE CORPORATION (JP) | 2006-08-03 | — | — | US | claimed |
| EP-4329730-A2 | A SPECIFIC COMBINATION OF LIPIDS AND METHODS AND USES RELATED THERETO | Helsingin Yliopisto (FI) | 2024-03-06 | — | — | EP | disclosed |
| EP-3845580-B1 | ALIPHATIC POLYESTER WITH HIGH ELONGATION | CHANG CHUN PLASTICS CO LTD (TW) | 2023-10-25 | — | — | EP | disclosed |
| US-20210206914-A1 | ALIPHATIC POLYESTER WITH HIGH ELONGATION | CHANG CHUN PLASTICS CO., LTD. (TW) | 2021-07-08 | — | — | US | disclosed |
| EP-3845580-A1 | ALIPHATIC POLYESTER WITH HIGH ELONGATION | Chang Chun Plastics Co., Ltd. (TW) | 2021-07-07 | — | — | EP | disclosed |
| WO-2018050484-A1 | LUBRICANT COMPOSITIONS CONTAINING DIUREA COMPOUNDS | BASF SE (DE) | 2018-03-22 | — | — | WO | disclosed |
| EP-3293246-A1 | LUBRICANT COMPOSITIONS CONTAINING DIUREA COMPOUNDS | BASF SE (DE) | 2018-03-14 | — | — | EP | disclosed |
| US-8445571-B2 | Processing agent for polyurethane elastomer fibers | TAKEMOTO YUSHI KABUSHIKI KAISHA (JP) | 2013-05-21 | — | — | US | disclosed |
| US-7572855-B2 | Nano-composite and compositions manufactured thereof | BRIDGESTONE CORPORATION (JP) | 2009-08-11 | — | — | US | disclosed |
| US-20090182087-A1 | NANO-COMPOSITE AND COMPOSITIONS THEREFROM | BRIDGESTONE CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20070293684-A1 | Method of preparing imidazolium surfactants | BRIDGESTONE CORPORATION | 2007-12-20 | — | — | US | disclosed |
| US-20070161734-A1 | Comprising clay and cationic mediator such as imidazolium compound wherein cationic mediator comprises hydrophobic unit and cationic unit; use in preparing products such as tires with improved and well-balanced properties including gas impermeability, cure rates, and superior mechanical characteristics | BRIDGESTONE CORPORATION (JP) | 2007-07-12 | — | — | US | disclosed |
| EP-1730228-A1 | NANO-COMPOSITE AND METHOD THEREOF | Bridgestone Corporation (JP) | 2006-12-13 | — | — | EP | disclosed |
| US-20060173115-A1 | Nano-composite and compositions manufactured thereof | BRIDGESTONE CORPORATION (JP) | 2006-08-03 | — | — | US | disclosed |
| WO-2005095506-A1 | NANO-COMPOSITE AND METHOD THEREOF | BRIDGESTONE CORPORATION (JP) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293684-A1 | Method of preparing imidazolium surfactants | SMARCC2, SMARCC1, ITPR3 | LMNA 952/4885KDM4C 3733/4885KDM4A 3860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.